Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

Vistagen Therapeutics Inc (VTGN) reports positive Phase 3 trial outcomes and financial stability, despite rising operational ...

Masking social anxiety: why some Hong Kong teens still use face coverings Selective mutism (SM) is an anxiety disorder that usually affects children. It describes when a person is unable to speak ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...

Dating with social anxiety? Fear of judgment and awkward moments can be overwhelming, but with the right strategies, you can ...

Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Social technologies present a unique paradox—they can be connectors and disruptors. They can simultaneously offer lifelines ...

The musical centers on Evan Hansen, a lonely high school teenager who suffers from social anxiety. When a letter he writes ...

People who experience high levels of social anxiety may show a weaker cardiovascular response to stressful situations, and ...